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| INTRODUC TI ON
Platelet function disorders (PFDs) are among the most common hereditary bleeding disorders, exposing affected patients to the risk of bleeding, particularly in the context of trauma and medical inter-
ventions.
1,2 Diagnosing PFD is, however, cumbersome, and many patients are probably not identified. 3 While severe PFD such as Glanzmann thrombasthenia, Bernard-Soulier syndrome, or syndromic disorders are easier to recognize, diagnosis is much more elusive in the majority of PFD patients. The diagnostic evaluation requires laboratory assays that are technically challenging, time-consuming, and difficult to interpret. 4 These tests tend also to be available in specialized laboratories only. 3 In addition, complex preanalytic requirements often necessitate blood drawing on site at the laboratory rather than having the sample shipped from farther afield. 5, 6 It is therefore important to select the patients for referral adequately.
Structured BATs such as from the International Society on
Thrombosis and Haemostasis (ISTH-BAT) may be utilized as a screening instrument in specific patients and implemented in the diagnostic evaluation, thereby triggering a referral. The ISTH-BAT is an instrument to record both the presence and the severity of bleeding symptoms covering 14 important sites of bleeding in patients. 7, 8 It has been validated extensively in patients with suspected von Willebrand disease (VWD). [9] [10] [11] The diagnostic utility of the ISTH-BAT with regard to platelet function disorders is, however, still elusive. 12 With respect to adult patients, it has never been studied within the appropriate target population, namely, consecutive patients referred for evaluation of a suspected bleeding disorder.
With the present study, we aimed to assess the diagnostic value of the ISTH-BAT of the International Society on Thrombosis and
Haemostasis for platelet function disorders in a representative cohort of patients.
| ME THODS

| Study design, setting, and population
We included all patients older than 18 years of age referred with a suspected bleeding disorder to a specialized outpatient clinic of Clinical data were prospectively recorded using an established in-house questionnaire as well as the ISTH-BAT sheet in the electronic hospital database. Laboratory data were stored accordingly.
Patient files were coded using an in-house identification system and data were retrieved by two investigators working in parallel (MA/ JK, MN). All patients signed informed consent forms and the ethics committee approved the study protocol (No. 02289).
| Evaluation of patients and determination of ISTH-BAT
The evaluation of patients was done using a standardized protocol as proposed in previous recommendations. 4, 7, [13] [14] [15] Before consultation, patients completed a 13-item, in-house questionnaire assessing the presence and severity of bleeding at specific organs, including the skin, nose, oral cavity, gastrointestinal and urogenital systems, joints and muscles, bleeding in association with minor injuries, dental procedures, surgery, transfusion requirements, bleeding after ingestion of drugs known to affect hemostasis, and family history. 16 During the consultation, trained resident physicians took detailed history using a standardized form and applied the ISTH-BAT. 7, 8 The scores
were applied prior to laboratory testing and physicians were not aware of any laboratory test results. The ISTH-BAT scorings were challenged by a second experienced physician (attending). Patients were instructed to stop anticoagulant treatment, antiaggregant treatment, nonsteroidal antirheumatic drugs, and/or selective serotonin reuptake inhibitors 10 days prior to consultation. Potential bleeding stigmata including petechia, hematomas, as well as signs of amyloidosis, telangiectasia, or joint hyperflexibility, were documented after a thorough physical examination.
| Handling of samples
To prevent preanalytical errors, a standardized protocol was implemented for blood drawing and preparation of blood samples. 
Essentials
• The utility of bleeding assessment tools regarding platelet function disorders is still elusive.
• We studied consecutive patients in a prospective cohort study in a tertiary hospital.
• Substantially higher scorings were observed in patients with platelet function disorders.
• Bleeding assessment tools might provide a useful screening tool. Platelet flow cytometry was conducted as previously described. 16 Surface glycoproteins (GPs) were analyzed using antihu- house reference values had been previously established. 16 As a control, a sample from a healthy volunteer was analyzed in parallel with each run. Flow cytometric analysis was repeated once with different control platelets to confirm the results.
| Laboratory evaluation
| Definition of diagnoses
Bleeding disorders were diagnosed following current recommendations. Type 1 VWD was diagnosed with repeatable (two times)
VWF:GPIbM levels of 0.05 to 0.4 U/mL and VWF:Ag of 0.05 to 0.4 U/ mL, a VWF:GPIbM/VWF:Ag ratio of >0.7, a normal multimer pattern, and an appropriate bleeding history. [21] [22] [23] [24] [25] The threshold of 0.4 U/mL was chosen rather than a 0.3 in order to simplify treatment decisions in clinical practice. 26 Type 2 VWD was diagnosed according to ISTH criteria. 23 Low VWF was diagnosed in patients with VWF:GPIbM or VWF:Ag below 0.5 U/mL, not meeting the criteria mentioned, and associated with blood group O.
14 Hemophilia and other single-factor deficiencies were diagnosed according to current definitions.
27
Interpretation of LTA and flow cytometry was done according to previous recommendations and established in-house reference ranges 16 by three experienced individuals; discrepancies were resolved by discussion. and convulxin 1, 16, 32 ; (f) α-granule disorders, defined as a reduced expression and/or secretion of P-selectin, associated with varying impaired aggregation after stimulation with collagen and epinephrine 1, 16 ; (g) decreased generation of procoagulant (COAT) platelets, defined as an impaired binding of Annexin-V after incubation with convulxin and thrombin 16 ; (h) complex disorders, defined as defects in a number of agonists (LTA) and/or several flow cytometry results that cannot be attributed to any of the disorders mentioned.
We defined a "bleeder of undefined cause" as a patient with an abnormal ISTH-BAT (male ≥4 points; female ≥6 points) if results of all other tests mentioned in the diagnostic evaluation were normal and no bleeding disorder was identified. [33] [34] [35] Patients who did not have hemostatic disorders but did have systemic disorders associated with bleeding symptoms (e.g. hereditary telangiectasia and thrombocytopenia) were categorized as having "systemic disorders."
| Statistical analysis
Descriptive statistics were used to characterize the study population (numbers/percent or median/interquartile range as appropriate).
To evaluate the ISTH-BAT ability to discriminate between patients with or without a demonstrable platelet defect on platelet function testing, a receiver-operating characteristic curve analysis was per- 
| RE SULTS
| Patient characteristics
Between January 2012 and March 2017, 555 patients were referred with a suspected bleeding disorder and were included in the study cohort ( Figure 1A 
| Type of bleeding disorders
A bleeding disorder was diagnosed in 288 patients (51.9%; Figure 1 ; and a systemic disorder in 38 cases (6.9%).
| Subgroups of PFD
Of 118 patients with a possible PFD, a confirmed subgroup could be established in 54 patients (46%). In contrast, diagnostic evaluation was not conclusive in 64 patients (54%). Distributions of PFD subgroups according to these two diagnostic groups are shown in Table 2 . Gi-like defects were found most frequently (32%), followed by complex disorders (28%), and diminished procoagulant COAT platelets (8%).
| Results of ISTH-BAT scorings according to diagnosis
The median value of the ISTH-BAT bleeding score in patients without a bleeding disorder was 2 (IQR 1, 4). In contrast, the ISTH-BAT 
| Predictive value of ISTH-BAT
The ROC curve analysis demonstrated an area under the curve 
| D ISCUSS I ON
In our cohort of consecutive patients assessed for a suspected bleeding disorder in clinical practice, we identified 54 patients with a confirmed PFD (9.7%) and 64 patients with a possible PFD (11.5%). Results Abbreviations: IQR, interquartile range; SSRI, selective serotonin reuptake inhibitors; VWF:C, von Willebrand factor antigen. a Diagnosis of a platelet function disorder was made using light transmission aggregometry and platelet flow cytometry. "Confirmed platelet function disorder" was defined as abnormal results in repeated light transmission aggregometry/flow cytometry measurements in the absence of other disorders, "possible platelet function disorder" as an abnormal result in one measurement available, inconclusive results or presence of concomitant disorder.
TA B L E 1 Characteristics of patients referred with a suspected bleeding disorder (n = 555; 2012-2017)
of ISTH-BAT were substantially higher in patients with possible and confirmed PFD compared to patients without a bleeding disorder. The predictive value of ISTH-BAT for the presence of PFD was good.
Our results are essentially in line with previous investigations conducted in different settings and using other study designs. In a subgroup of patients studied in a pediatric setting, the ISTH score was higher in 5 patients with a possible PFD (median 3) compared to patients without a bleeding disorder (median 1). 30 Rashid and colleagues compared ISTH-BAT scorings between patients with suspected PFD and healthy volunteers in Pakistan and found a statistically significant difference (median 2 versus median 0). 36 microscopy). Thus, the particular molecular defect in many patients could not be found. However, our results are in line with a previous study using ATP-release 37 and we do not anticipate that this introduced any bias.
Our results suggest that ISTH-BAT is a useful screening tool in patients with suspected PFD. This is particularly supported by the high sensitivity. The ISTH-BAT might be applied for triggering a referral of patients with any bleeding tendency at all (including patients with PFD as well as VWD), or for triggering platelet function studies in patients with normal first-line test results. We do not believe that the ISTH-BAT is able to discriminate different types of mild bleeding disorders, e.g. PFD from VWD, and we do not believe that the ISTH-BAT might replace platelet function studies. Our study
was not designed to demonstrate a respective difference and two observations suggest the opposite: (a) the specificity is moderate only, suggesting a relevant number of patients with abnormal ISTH-BAT associated with other disorders than PFD and (b) a widely overlapping distribution of ISTH-BAT scorings among patients with PFD, VWD, and other disorders. This study must be replicated in other settings and employing alternative platelet function assays as well.
In conclusion, in a large study of patients referred for suspected bleeding disorders in clinical practice, patients with PFD had substantially higher ISTH-BAT scorings than patients without and the predictive value of ISTH-BAT was good. Our results suggest that ISTH is a useful screening tool for PFD in clinical practice.
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